beta-alanine has been researched along with Anterior Circulation Transient Ischemic Attack in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events." | 8.90 | Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. ( Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014) |
| "New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation." | 8.88 | An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012) |
| "This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both "new starters" on dabigatran and "switchers" to dabigatran from warfarin." | 7.80 | Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
| "The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed." | 7.78 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. ( Easton, JD; Johnston, SC; Kamel, H; Kim, AS, 2012) |
| "To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF." | 7.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
| "Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events." | 4.90 | Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. ( Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014) |
| "New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation." | 4.88 | An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012) |
| "This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both "new starters" on dabigatran and "switchers" to dabigatran from warfarin." | 3.80 | Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
| "The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed." | 3.78 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. ( Easton, JD; Johnston, SC; Kamel, H; Kim, AS, 2012) |
| "To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF." | 3.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, C | 1 |
| Zhu, L | 1 |
| Wu, J | 1 |
| Fang, S | 1 |
| Marrone, LC | 2 |
| Marrone, AC | 2 |
| Diener, HC | 1 |
| Weber, R | 1 |
| Sardar, P | 1 |
| Nairooz, R | 1 |
| Chatterjee, S | 1 |
| Wetterslev, J | 1 |
| Ghosh, J | 1 |
| Aronow, WS | 1 |
| Bin Abdulhak, AA | 1 |
| Khan, AR | 1 |
| Wimmer, AP | 1 |
| Larsen, TB | 1 |
| Rasmussen, LH | 1 |
| Gorst-Rasmussen, A | 1 |
| Skjøth, F | 1 |
| Lane, DA | 1 |
| Lip, GY | 1 |
| Calkins, H | 1 |
| Gerstenfeld, EP | 1 |
| Schilling, R | 1 |
| Verma, A | 1 |
| Willems, S | 1 |
| Sengupta, N | 1 |
| Feuerstein, JD | 1 |
| Patwardhan, VR | 1 |
| Tapper, EB | 1 |
| Ketwaroo, GA | 1 |
| Thaker, AM | 1 |
| Leffler, DA | 1 |
| Cantürk, E | 1 |
| Karaca, O | 1 |
| Omaygenç, O | 1 |
| Kızılırmak, F | 1 |
| Güler, E | 1 |
| Eikelboom, JW | 1 |
| Bosch, J | 1 |
| Freeman, JV | 1 |
| Zhu, RP | 1 |
| Owens, DK | 1 |
| Garber, AM | 1 |
| Hutton, DW | 1 |
| Go, AS | 1 |
| Wang, PJ | 1 |
| Turakhia, MP | 1 |
| Kamel, H | 1 |
| Johnston, SC | 1 |
| Easton, JD | 1 |
| Kim, AS | 1 |
| Mantha, S | 1 |
| Ansell, J | 1 |
| Spyropoulos, AC | 1 |
| Douketis, JD | 1 |
| Gerotziafas, G | 1 |
| Kaatz, S | 1 |
| Ortel, TL | 1 |
| Schulman, S | 1 |
| Aalbers, J | 1 |
| Hardy, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for beta-alanine and Anterior Circulation Transient Ischemic Attack
| Article | Year |
|---|---|
[New anticoagulants in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Hum | 2013 |
Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr | 2014 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tri | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Pr | 2012 |
12 other studies available for beta-alanine and Anterior Circulation Transient Ischemic Attack
| Article | Year |
|---|---|
What if a patient with atrial fibrillation and anticoagulant treatment is suffering from acute ischemia stroke?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Ischemic Attack, Transient; Male; Stroke; Thro | 2013 |
Acute ischemic stroke and new anticoagulants -- how to act in the acute phase of stroke?.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Ischemic Attack, Transient; Male; Stroke; Thro | 2013 |
Dabigatran in catheter ablation of atrial fibrillation: a call for a randomized control trial.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Humans; Ischemic Attack, Trans | 2014 |
Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2014 |
RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Humans; Ischemic Attack, Trans | 2015 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; E | 2015 |
Case images: warfarin-induced skin necrosis: a 'novel' solution to an old problem.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Hu | 2014 |
Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ischemic Attack, T | 2015 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben | 2011 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefi | 2012 |
Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report.
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Brain; Dabigatran; Fibrinolytic Agents; Humans; | 2012 |
Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I | 2012 |